Login to Your Account



FDA Sends Second Approvable Letter For Celgene's Thalomid

By Aaron Lorenzo


Wednesday, November 16, 2005
Celgene Corp.'s Thalomid (thalidomide) again is approvable for multiple myeloma, but only after certain conditions are met, the FDA said. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription